APA (7th ed.) Citation

Roth, E. M., Taskinen, M., Ginsberg, H. N., Kastelein, J. J. P., Colhoun, H. M., Robinson, J. G., . . . Baccara-Dinet, M. T. (2014). Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial. International Journal of Cardiology, 176(1), 55. https://doi.org/10.1016/j.ijcard.2014.06.049

Chicago Style (17th ed.) Citation

Roth, Eli M., Marja-Riitta Taskinen, Henry N. Ginsberg, John J. P. Kastelein, Helen M. Colhoun, Jennifer G. Robinson, Laurence Merlet, Robert Pordy, and Marie T. Baccara-Dinet. "Monotherapy with the PCSK9 Inhibitor Alirocumab Versus Ezetimibe in Patients with Hypercholesterolemia: Results of a 24 Week, Double-blind, Randomized Phase 3 Trial." International Journal of Cardiology 176, no. 1 (2014): 55. https://doi.org/10.1016/j.ijcard.2014.06.049.

MLA (9th ed.) Citation

Roth, Eli M., et al. "Monotherapy with the PCSK9 Inhibitor Alirocumab Versus Ezetimibe in Patients with Hypercholesterolemia: Results of a 24 Week, Double-blind, Randomized Phase 3 Trial." International Journal of Cardiology, vol. 176, no. 1, 2014, p. 55, https://doi.org/10.1016/j.ijcard.2014.06.049.